Imagine a smart internal drain for people whose hearts can't pump fluid out of their bodies. Instead of taking harsh pills that damage the kidneys, this device gently removes excess water and salt and sends it to the bladder. Doctors can adjust the settings remotely from their office, keeping patients out of the hospital.
Heart failure patients often become resistant to diuretics, leading to frequent, costly hospitalizations and a median life expectancy of only 18 months once resistance sets in.
An implantable peritoneal ultrafiltration device (IPUD) and a remote management platform for physicians to control fluid removal.
If you are a cardiovascular implant specialist dealing with the 30% of heart failure patients who resist medication — this project developed an implantable ultrafiltration device that removes isotonic fluid continuously. This allows for a shift from hospital-based care to home-based management.
If you are a remote patient monitoring provider dealing with high readmission rates — this project developed a remote treatment management platform that lets physicians adjust therapy based on real-time data. This prevents the 25% of patients who are typically readmitted within 30 days.
If you are a private hospital network dealing with the fact that US hospitals lose money on heart failure hospitalizations — this project developed a system to move fluid congestion care to the home. This reduces the 2 million annual congestion-driven hospitalizations.
The system aims to save billions of dollars/euro by reducing repeat hospitalizations for fluid overload in CHF patients.
The target market is significant, as roughly 60 million people worldwide suffer from chronic congestive heart failure.
Based on available project data, the technology is developed by Paragate Medical Ltd, but specific licensing terms are not provided.
Physicians use a remote treatment management platform to continuously control patient conditions and adjust therapy based on monitoring data.
The project period is from August 1, 2023, to July 31, 2025.
The project is led by a single Israeli SME, Paragate Medical Ltd, with a 100% industry ratio. This lean structure suggests a high level of internal control over the IP and a fast-track approach to commercialization, though it lacks academic or research partners for external validation within the consortium.
Contact Paragate Medical Ltd in Israel
Contact us to explore licensing opportunities for the IPUD system.
